Biomedical Engineering Reference
In-Depth Information
experiments) since it does not seem feasible to setup a unique experiment to
estimate the numerous parameters of those models. Hopefully, the development of
new methodologies together with the better accessibility of relevant biological
data will allow the development of an integrative platform to support research
progresses in this area and the development of therapeutics.
References
1. Friberg, L.E., Henningsson, A., Maas, H., Nguyen, L., Karlsson, M.O.: Model of
chemotherapy-induced myelosuppression with parameter consistency across drugs. J. Clin.
Oncol. 20(24), 4713-4721 (2002)
2. Miller,
A.B.,
Hoogstraten,
B.,
Staquet,
M.,
Winkler,
A.:
Reporting
results
of
cancer
treatment. Cancer 47, 207-214 (1981)
3. Therasse, P., Arbuck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., et al.: New
guidelines to evaluate the response to treatment in solid tumors. european organization for
research and treatment of cancer, national cancer institute of the united states, national cancer
institute of canada. J. Natl. Cancer. Inst. 92(3), 205-216 (2000)
4. Laird, A.K.: Dynamics of tumor growth. Br. J. Cancer 13, 490-502 (1964)
5. Simpson-Herren, L., Lloyd, H.H.: Kinetic parameters and growth curves for experimental
tumor systems. Cancer Chemothe. Rep. 54(3), 143-174 (1970)
6. Sullivan, P.W., Salmon, S.E.: Kinetics of tumor growth and regression in IgG multiple
myeloma. J. Clin. Investig. 51(7), 1697-1708 (1972)
7. Norton, L., Simon, R., Brereton, H.D., Bogden, A.E.: Predicting the course of gompertzian
growth. Nature 264(5586), 542-545 (1976)
8. Norton,
L.:
A
gompertzian
model
of
human
breast
cancer
growth.
Cancer
Res.
48,
7067-7071 (1988)
9. Citron, M.L., Berry, D.A., Cirrincione, C., Hudis, C., Winer, E.P., et al.: Randomized trial of
dose-dense versus conventionally scheduled and sequential versus concurrent combination
chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer:
first report of Intergroup trial C9741/cancer and leukemia group B Trial 9741. J. Clin. Oncol.
21, 1431-1439 (2003)
10. Simeoni, M., Magni, P., Cammia, C., De Nicolao, G., Croci, V., et al.: Predictive
pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models
after administration of anticancer agents. Cancer Res. 64(3), 1094-1101 (2004)
11. Wang, Y., Sung, C., Dartois, C., Ramchandani, R., Booth, B.P., et al.: Elucidation of
relationship between tumor size and survival in non-small-cell lung cancer patients can aid early
decision making in clinical drug development. Clin. Pharmacol. Ther. 86(2), 167-174 (2009)
12. Tham, L.S., Wang, L., Soo, R.A., Lee, S.C., Lee, H.S., et al.: A pharmacodynamic model for
the time course of tumor shrinkage by gemcitabine ? carboplatin in non-small cell lung
cancer patients. Clin. Cancer Res. 14(13), 4213-4218 (2008)
13. Claret, L., Girard, P., Hoff, P.M., Van Cutsem, E., Zuideveld, K.P., et al.: Model-based
prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor
dynamics. J. Clin. Oncol. 27(25), 4103-4108 (2009)
14. Houk, B.E., Bello, C.L., Poland, B., Rosen, L.S., Demetri, G.D., et al.: Relationship between
exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of
a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother. Pharmacol. 66(2),
357-371 (2010)
15. Tracqui, P., Cruywagen, G.C., Woodward, D.E., Bartoo, G.T., Murray, J.D., et al.: A
mathematical model of glioma growth: the effect of chemotherapy on spatio-temporal
growth. Cell Prolif. 28(1), 17-31 (1995)
Search WWH ::
Custom Search